{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T23:37:36Z","timestamp":1789342656229,"version":"build-2803163510"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004572","name":"National Health Commission of the People's Republic of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004572","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100016983","name":"Shanghai Clinical Research Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100016983","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomaterials"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.biomaterials.2024.122480","type":"journal-article","created":{"date-parts":[[2024,1,21]],"date-time":"2024-01-21T04:25:39Z","timestamp":1705811139000},"page":"122480","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"special_numbering":"C","title":["Hypoxia-activated cascade nanovaccine for synergistic chemoembolization-immune therapy of hepatocellular carcinoma"],"prefix":"10.1016","volume":"306","author":[{"given":"Qin","family":"Shi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongjie","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5043-7700","authenticated-orcid":false,"given":"Songjiang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3225-1467","authenticated-orcid":false,"given":"Jiaze","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minjie","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zihan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingqin","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianjun","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengxiang","family":"Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daru","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaojun","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongbin","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingxiao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4601-9853","authenticated-orcid":false,"given":"Zhiping","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.biomaterials.2024.122480_bib1","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA A Cancer J. Clin."},{"issue":"10127","key":"10.1016\/j.biomaterials.2024.122480_bib2","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/S0140-6736(18)30010-2","article-title":"Hepatocellular carcinoma","volume":"391","author":"Forner","year":"2018","journal-title":"Lancet"},{"issue":"10360","key":"10.1016\/j.biomaterials.2024.122480_bib3","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1016\/S0140-6736(22)01200-4","article-title":"Hepatocellular carcinoma","volume":"400","author":"Vogel","year":"2022","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.biomaterials.2024.122480_bib4","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.jhep.2021.11.018","article-title":"BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update","volume":"76","author":"Reig","year":"2022","journal-title":"J. Hepatol."},{"issue":"6","key":"10.1016\/j.biomaterials.2024.122480_bib5","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.annonc.2021.02.014","article-title":"Updated treatment recommendations for hepatocellular carcinoma (HCC) from the ESMO Clinical Practice Guidelines","volume":"32","author":"Vogel","year":"2021","journal-title":"Ann. Oncol."},{"issue":"33","key":"10.1016\/j.biomaterials.2024.122480_bib6","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202301352","article-title":"A sodium alginate-based multifunctional nanoplatform for synergistic chemo-immunotherapy of hepatocellular carcinoma","volume":"35","author":"Huang","year":"2023","journal-title":"Adv. Mater."},{"issue":"5","key":"10.1016\/j.biomaterials.2024.122480_bib7","doi-asserted-by":"crossref","first-page":"8493","DOI":"10.1021\/acsnano.2c03768","article-title":"Shape designed implanted drug delivery system for in situ hepatocellular carcinoma therapy","volume":"16","author":"Zhao","year":"2022","journal-title":"ACS Nano"},{"issue":"5","key":"10.1016\/j.biomaterials.2024.122480_bib8","article-title":"Efficacy and safety of frontline systemic therapy for advanced HCC: a network meta-analysis of landmark phase III trials","volume":"5","author":"Fulgenzi","year":"2023","journal-title":"JHEP Rep"},{"issue":"4","key":"10.1016\/j.biomaterials.2024.122480_bib9","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/s41575-022-00704-9","article-title":"Evolving therapeutic landscape of advanced hepatocellular carcinoma","volume":"20","author":"Yang","year":"2023","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"20","key":"10.1016\/j.biomaterials.2024.122480_bib10","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"26","key":"10.1016\/j.biomaterials.2024.122480_bib11","article-title":"Preclinical development and validation of translational temperature sensitive iodized oil emulsion mediated transcatheter arterial chemo-immuno-embolization for the treatment of hepatocellular carcinoma","volume":"12","author":"Kim","year":"2023","journal-title":"Adv. Healthcare Mater."},{"issue":"3","key":"10.1016\/j.biomaterials.2024.122480_bib12","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1200\/JCO.19.01307","article-title":"Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind, phase III trial","volume":"38","author":"Finn","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.biomaterials.2024.122480_bib13","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.nantod.2019.04.005","article-title":"Designing inorganic nanomaterials for vaccines and immunotherapies","volume":"27","author":"Hess","year":"2019","journal-title":"Nano Today"},{"issue":"4","key":"10.1016\/j.biomaterials.2024.122480_bib14","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1038\/s41565-022-01296-w","article-title":"A nanoadjuvant that dynamically coordinates innate immune stimuli activation enhances cancer immunotherapy and reduces immune cell exhaustion","volume":"18","author":"Jin","year":"2023","journal-title":"Nat. Nanotechnol."},{"issue":"12","key":"10.1016\/j.biomaterials.2024.122480_bib15","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1038\/s41565-022-01225-x","article-title":"Zinc cyclic di-AMP nanoparticles target and suppress tumours via endothelial STING activation and tumour-associated macrophage reinvigoration","volume":"17","author":"Yang","year":"2022","journal-title":"Nat. Nanotechnol."},{"issue":"9","key":"10.1016\/j.biomaterials.2024.122480_bib16","doi-asserted-by":"crossref","first-page":"15226","DOI":"10.1021\/acsnano.2c06560","article-title":"In situ programming of nanovaccines for lymph node-targeted delivery and cancer immunotherapy","volume":"16","author":"Jin","year":"2022","journal-title":"ACS Nano"},{"issue":"10","key":"10.1016\/j.biomaterials.2024.122480_bib17","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aaz4204","article-title":"Localized cocktail chemoimmunotherapy after in situ gelation to trigger robust systemic antitumor immune responses","volume":"6","author":"Chao","year":"2020","journal-title":"Sci. Adv."},{"key":"10.1016\/j.biomaterials.2024.122480_bib18","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.jconrel.2023.09.042","article-title":"Drug-drug conjugates self-assembled nanomedicines triggered photo-\/immuno- therapy for synergistic cancer treatments","volume":"363","author":"Qu","year":"2023","journal-title":"J. Contr. Release"},{"issue":"42","key":"10.1016\/j.biomaterials.2024.122480_bib19","doi-asserted-by":"crossref","DOI":"10.1002\/adma.201903242","article-title":"A designer scaffold with immune nanoconverters for reverting immunosuppression and enhancing immune checkpoint blockade therapy","volume":"31","author":"Phuengkham","year":"2019","journal-title":"Adv. Mater."},{"issue":"2","key":"10.1016\/j.biomaterials.2024.122480_bib20","article-title":"The use of nanotechnology to combat liver cancer: progress and perspectives","author":"Mintz","year":"1876","journal-title":"Biochim. Biophys. Acta Rev. Canc"},{"issue":"1","key":"10.1016\/j.biomaterials.2024.122480_bib21","doi-asserted-by":"crossref","first-page":"4321","DOI":"10.1038\/s41467-018-06655-7","article-title":"Nanoscale metal-organic frameworks for mitochondria-targeted radiotherapy-radiodynamic therapy","volume":"9","author":"Ni","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.biomaterials.2024.122480_bib22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.biomaterials.2016.04.034","article-title":"Nanoscale metal-organic frameworks for combined photodynamic & radiation therapy in cancer treatment","volume":"97","author":"Liu","year":"2016","journal-title":"Biomaterials"},{"issue":"1","key":"10.1016\/j.biomaterials.2024.122480_bib23","doi-asserted-by":"crossref","DOI":"10.1002\/adhm.201900996","article-title":"Photodynamic therapy combined with antihypoxic signaling and CpG adjuvant as an in situ tumor vaccine based on metal-organic framework nanoparticles to boost cancer immunotherapy","volume":"9","author":"Cai","year":"2020","journal-title":"Adv. Healthcare Mater."},{"issue":"10","key":"10.1016\/j.biomaterials.2024.122480_bib24","doi-asserted-by":"crossref","DOI":"10.1002\/anie.202215307","article-title":"ZIF-8 nanoparticles evoke pyroptosis for high-efficiency cancer immunotherapy","volume":"62","author":"Ding","year":"2023","journal-title":"Angew. Chem., Int. Ed. Engl."},{"issue":"20","key":"10.1016\/j.biomaterials.2024.122480_bib25","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202102500","article-title":"Engineering a smart agent for enhanced immunotherapy effect by simultaneously blocking PD-L1 and CTLA-4","volume":"8","author":"Jiang","year":"2021","journal-title":"Adv. Sci."},{"issue":"28","key":"10.1016\/j.biomaterials.2024.122480_bib26","doi-asserted-by":"crossref","first-page":"6128","DOI":"10.1039\/D0TB00193G","article-title":"A phosphorylcholine-based zwitterionic copolymer coated ZIF-8 nanodrug with a long circulation time and charged conversion for enhanced chemotherapy","volume":"8","author":"Xie","year":"2020","journal-title":"J. Mater. Chem. B"},{"issue":"44","key":"10.1016\/j.biomaterials.2024.122480_bib27","doi-asserted-by":"crossref","first-page":"21030","DOI":"10.1039\/C9NR06558J","article-title":"Recent advancement of imidazolate framework (ZIF-8) based nanoformulations for synergistic tumor therapy","volume":"11","author":"Gao","year":"2019","journal-title":"Nanoscale"},{"issue":"2","key":"10.1016\/j.biomaterials.2024.122480_bib28","doi-asserted-by":"crossref","first-page":"216","DOI":"10.21037\/hbsn-22-469","article-title":"A review of 2022 Chinese clinical guidelines on the management of hepatocellular carcinoma: updates and insights","volume":"12","author":"Xie","year":"2023","journal-title":"Hepatobiliary Surg. Nutr."},{"issue":"1","key":"10.1016\/j.biomaterials.2024.122480_bib29","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.jhep.2023.02.032","article-title":"TREM2+ macrophages suppress CD8+ T-cell infiltration after transarterial chemoembolisation in hepatocellular carcinoma","volume":"79","author":"Tan","year":"2023","journal-title":"J. Hepatol."},{"issue":"9","key":"10.1016\/j.biomaterials.2024.122480_bib30","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003311","article-title":"Trans-arterial chemoembolization as a loco-regional inducer of immunogenic cell death in hepatocellular carcinoma: implications for immunotherapy","volume":"9","author":"Pinato","year":"2021","journal-title":"J. Immunother. Cancer."},{"issue":"1","key":"10.1016\/j.biomaterials.2024.122480_bib31","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/s41392-022-01235-0","article-title":"Transarterial chemoembolization with PD-(L)1 inhibitors plus molecular targeted therapies for hepatocellular carcinoma (CHANCE001)","volume":"8","author":"Zhu","year":"2023","journal-title":"Signal Transduct. Targeted Ther."},{"issue":"6","key":"10.1016\/j.biomaterials.2024.122480_bib32","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-004205","article-title":"Integrated use of PD-1 inhibition and transarterial chemoembolization for hepatocellular carcinoma: evaluation of safety and efficacy in a retrospective, propensity score-matched study","volume":"10","author":"Marinelli","year":"2022","journal-title":"J. Immunother. Cancer."},{"issue":"5","key":"10.1016\/j.biomaterials.2024.122480_bib33","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/s41575-020-00395-0","article-title":"Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma","volume":"18","author":"Llovet","year":"2021","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"2","key":"10.1016\/j.biomaterials.2024.122480_bib34","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1021\/acsnano.6b08731","article-title":"Tumor-penetrating nanoparticles for enhanced anticancer activity of combined photodynamic and hypoxia-activated therapy","volume":"11","author":"Wang","year":"2017","journal-title":"ACS Nano"},{"issue":"10","key":"10.1016\/j.biomaterials.2024.122480_bib35","doi-asserted-by":"crossref","DOI":"10.1002\/adhm.202002036","article-title":"Tumor microenvironment triggered cascade-activation nanoplatform for synergistic and precise treatment of hepatocellular carcinoma","volume":"10","author":"Xin","year":"2021","journal-title":"Adv. Healthcare Mater."},{"key":"10.1016\/j.biomaterials.2024.122480_bib36","doi-asserted-by":"crossref","first-page":"421","DOI":"10.2147\/JHC.S304275","article-title":"Phase I trial on arterial embolization with hypoxia activated tirapazamine for unresectable hepatocellular carcinoma","volume":"8","author":"Abi-Jaoudeh","year":"2021","journal-title":"J. Hepatocell. Carcinoma"},{"issue":"1","key":"10.1016\/j.biomaterials.2024.122480_bib37","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s12951-022-01247-6","article-title":"A tumor microenvironment-responsive poly(amidoamine) dendrimer nanoplatform for hypoxia-responsive chemo\/chemodynamic therapy","volume":"20","author":"Hao","year":"2022","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.biomaterials.2024.122480_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2022.121911","article-title":"T-cell engaging poly(lactic-co-glycolic acid) nanoparticles as a modular platform to induce a potent cytotoxic immunogenic response against PD-L1 overexpressing cancer","volume":"291","author":"Duwa","year":"2022","journal-title":"Biomaterials"},{"issue":"1","key":"10.1016\/j.biomaterials.2024.122480_bib39","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-021-22311-z","article-title":"Intratumoral immunotherapy using platelet-cloaked nanoparticles enhances antitumor immunity in solid tumors","volume":"12","author":"Bahmani","year":"2021","journal-title":"Nat. Commun."},{"issue":"17","key":"10.1016\/j.biomaterials.2024.122480_bib40","doi-asserted-by":"crossref","first-page":"5918","DOI":"10.1039\/D3BM00813D","article-title":"Metal-organic-framework-based pyroptosis nanotuner with long blood circulation for augmented chemotherapy","volume":"11","author":"Zhu","year":"2023","journal-title":"Biomater. Sci."},{"key":"10.1016\/j.biomaterials.2024.122480_bib41","doi-asserted-by":"crossref","first-page":"9437","DOI":"10.1039\/c2ra21087h","article-title":"Cytotoxicity and slow release of the anti-cancer drug doxorubicin from ZIF-8","volume":"2","author":"Vasconcelos","year":"2012","journal-title":"RSC Adv."},{"issue":"19","key":"10.1016\/j.biomaterials.2024.122480_bib42","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202102043","article-title":"Overcoming chemoimmunotherapy-induced immunosuppression by assemblable and depot forming immune modulating nanosuspension","volume":"8","author":"Jin","year":"2021","journal-title":"Adv. Sci."},{"issue":"1","key":"10.1016\/j.biomaterials.2024.122480_bib43","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1038\/s41467-017-01651-9","article-title":"Nano-enabled pancreas cancer immunotherapy using immunogenic cell death and reversing immunosuppression","volume":"8","author":"Lu","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.biomaterials.2024.122480_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.nantod.2020.100924","article-title":"Carrier-free nanoassembly of doxorubicin prodrug and siRNA for combinationally inducing immunogenic cell death and reversing immunosuppression","volume":"35","author":"Chen","year":"2020","journal-title":"Nano Today"},{"key":"10.1016\/j.biomaterials.2024.122480_bib45","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1111\/j.1600-065X.2007.00579.x","article-title":"The grateful dead: damage-associated molecular pattern molecules and reduction\/oxidation regulate immunity","volume":"220","author":"Lotze","year":"2007","journal-title":"Immunol. Rev."},{"issue":"10","key":"10.1016\/j.biomaterials.2024.122480_bib46","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1038\/nm.3931","article-title":"CD47 blockade triggers T cell-mediated destruction of immunogenic tumors","volume":"21","author":"Liu","year":"2015","journal-title":"Nat. Med."},{"key":"10.1016\/j.biomaterials.2024.122480_bib47","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.jconrel.2022.12.001","article-title":"A macrophage membrane-coated mesoporous silica nanoplatform inhibiting adenosine A2AR via in situ oxygen supply for immunotherapy","volume":"353","author":"Wen","year":"2023","journal-title":"J. Contr. Release"},{"issue":"6","key":"10.1016\/j.biomaterials.2024.122480_bib48","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/s41577-019-0127-6","article-title":"Macrophages as regulators of tumour immunity and immunotherapy","volume":"19","author":"DeNardo","year":"2019","journal-title":"Nat. Rev. Immunol."},{"issue":"1","key":"10.1016\/j.biomaterials.2024.122480_bib49","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/s13045-019-0760-3","article-title":"Tumor-associated macrophages in tumor metastasis: biological roles and clinical therapeutic applications","volume":"12","author":"Lin","year":"2019","journal-title":"J. Hematol. Oncol."},{"issue":"30","key":"10.1016\/j.biomaterials.2024.122480_bib50","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202202206","article-title":"S100A9 derived from chemoembolization-induced hypoxia governs mitochondrial function in hepatocellular carcinoma progression","volume":"9","author":"Zhong","year":"2022","journal-title":"Adv. Sci."}],"container-title":["Biomaterials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0142961224000140?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0142961224000140?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T17:23:13Z","timestamp":1758907393000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0142961224000140"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":50,"alternative-id":["S0142961224000140"],"URL":"https:\/\/doi.org\/10.1016\/j.biomaterials.2024.122480","relation":{},"ISSN":["0142-9612"],"issn-type":[{"value":"0142-9612","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hypoxia-activated cascade nanovaccine for synergistic chemoembolization-immune therapy of hepatocellular carcinoma","name":"articletitle","label":"Article Title"},{"value":"Biomaterials","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biomaterials.2024.122480","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"122480"}}